Of note, Kleinovink et al. have recently shown in tumour models of colon carcinoma that the addition of CTLA-4 blockade prior to bremachlorin-PDT leads to a significant reduction in tumour burden compared to either treatment alone [48]. The gene discussed is CTLA4; the disease is neoplasm.